Physician profile
Munib S Daudjee
NPI 1417141706
$5,481.91
in general payments reported to CMS, 2019-2025
38 companies · $1,724 in 2025
The $1,724 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $297 · 2020: $346 · 2021: $375 · 2022: $883 · 2023: $1,066 · 2024: $791 · 2025: $1,724.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,574 · Education: $7.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,573.53 |
| Education | $7.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,597.64 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $542.95 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $459.35 | 2019-2025 | Farxiga |
| Amgen INC. | $337.91 | 2019-2025 | Repatha, Repatha, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $276.93 | 2022-2025 | Xifaxan |
| Boston Scientific Corporation | $264.35 | 2024-2025 | General - Vascular Intervention |
| Glaxosmithkline, LLC. | $216.08 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amarin Pharma, INC. | $192.58 | 2020-2022 | |
| Supernus Pharmaceuticals, INC. | $176.60 | 2023-2025 | Qelbree, Qelbree |
| Axsome Therapeutics, INC. | $168.44 | 2025 | Symbravo |
| Intuitive Surgical, INC. | $161.57 | 2019 | |
| Madrigal Pharmaceuticals | $136.03 | 2025 | Rezdiffra |
| Bayer Healthcare Pharmaceuticals INC. | $123.40 | 2024-2025 | |
| Lilly USA, LLC | $122.43 | 2020-2024 | Mounjaro, Jardiance, Zepbound |
| Phathom Pharmaceuticals, INC. | $110.75 | 2025 | Voquezna |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $75.47 | 2023-2025 | Veozah, Myrbetriq |
| Esperion Therapeutics, INC. | $63.22 | 2020-2024 | Nexletol |
| Abbott Laboratories | $62.88 | 2021-2024 | Freestyle Libre 3 |
| Pfizer INC. | $60.30 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $38.89 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.38 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $31.28 | 2020 | |
| Allergan, INC. | $28.97 | 2020 | |
| Horizon Therapeutics Plc | $28.29 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $24.62 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $19.79 | 2020 | |
| Antares Pharma, INC. | $18.39 | 2020 | |
| Arbor Pharmaceuticals, INC. | $17.27 | 2020 | |
| Dexcom, INC. | $16.36 | 2025 | Dexcom G6 Transmitter |
| Aytu Biopharma, INC. | $15.26 | 2020 | |
| Idorsia Pharmaceuticals US INC | $15.02 | 2023 | Quviviq |
| Medtronic, INC. | $15.00 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $14.77 | 2025 | Zoryve |
| Exact Sciences Corporation | $13.74 | 2023 | Cologuard Collection Kit |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Munib Daudjee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.